<DOC>
	<DOCNO>NCT01125748</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , 2-arm , 1-year study participant complete EXCELS study ( NCT00252135 ) receive long-term treatment Xolair . In addition , participant participate EXCELS study receive long-term ( ~5 year ) treatment Xolair allow enter study .</brief_summary>
	<brief_title>A Study Evaluating Persistency Response With Without Xolair ( Omalizumab ) After Long-term Therapy</brief_title>
	<detailed_description>The treatment designation participant reach primary efficacy endpoint ( 1 protocol-defined severe asthma exacerbation ) unblinded allow appropriate clinical intervention . Participants treatment designation unblinded remain study ongoing evaluation safety allow continue study drug know Xolair ( start study drug know Xolair placebo group ) .</detailed_description>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Signed Informed Consent Form ( ICF ) . In case minor , consent must give child 's parent legally authorize representative . Participants complete EXCELS study prior study must meet inclusion criterion enrollment EXCELS study . History positive skin test vitro reactivity aeroallergen . Continuous Xolair ( omalizumab ) exposure begin EXCELS study randomization study ( participant participate EXCELS study ) , within previous 5 year prior randomization study ( participant participate EXCELS study ) . For purpose study , continuous Xolair exposure define miss 25 % schedule Xolair dos . In addition , maximum 2 dos miss within last 6 month randomize study . For participant participate EXCELS study , misseddose rate base injection record . Patients participate EXCELS study must complete EXCELS study discontinue Xolair since completion EXCELS study . Diagnosis moderate severe persistent allergic asthma Xolair define per physician 's assessment . Stable dose current asthma therapy , addition Xolair , 2 month prior enrollment . Serum IgE level ≥ 30 ≤ 700 IU/mL initiation Xolair treatment ( prior EXCELS study enrollment earlier ) . Body weight ≥ 30 ≤ 150 kg . Treatment Xolair consistent US package insert ( USPI ) ( base dose table , recommend dose , administration , dose interval ) prior enrollment study . Participants participate EXCELS study must willing allow EXCELS study data use study part baseline demographic value ( forced expiratory volume 1 second [ FEV1 ] Asthma Control Test [ ACT ] ) , document ICF . Participation therapy trial plan participation follow year screen . Contraindication Xolair therapy ( eg , participant experience severe hypersensitivity reaction Xolair ) . Acute asthma exacerbation within 2 month immediately prior screening require following : Initiation systemic corticosteroid , increase dose systemic corticosteroid relative `` stable '' dose , double inhale corticosteroid ( ICS ) dosing , emergency room visit , hospitalization . Any significant , unstable , systemic disease ( eg , infection , hematologic , renal , hepatic , cardiovascular disease , gastrointestinal disease ) , recent hospitalization systemic disease within previous 2 month . Diagnosis active lung disease asthma . Having 10 packyears smoke history . Diagnosis cystic fibrosis . Use experimental drug within 30 day prior study screen . Unable unwilling comply study procedure visit ( eg , spirometry , blood draw ) . Have elevate serum IgE level reason allergy ( eg , parasite infection , hyperimmunoglobulin E syndrome , WiskottAldrich syndrome , bronchopulmonary aspergillosis ) . Pregnancy , lactation , plan pregnancy follow year .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>